



The new generation blood test: easy and effective







A HEALTHY LIFESTYLE AND REGULAR SCREENING COULD PREVENT COLORECTAL CANCER

Ask your physician if **Colox®** is suitable for you

COLORECTAL CANCER IN SWITZERLAND

- The 3rd most common cancer¹
- The 2nd most deadly cancer¹
- The risk of developing cancer increases with age
- The Ligue Suisse Contre le Cancer recommends colorectal cancer screening for men and women beginning at the age of 50²



per day due to



4'800
new cases per year
of colorectal cancer



1 in 20 individual risk of developing colorectal cancer after the age of 50

EARLY DETECTION IMPROVES THE CHANCES OF SURVIVAL

5-year survival rate:

> 95%

If detection is made at the precancerous stage of adenomatous polyps³

85%

If detection is made at early stages of the cancer⁴

8%

If detection is made at the most advanced stages of the cancer⁴

COLOX® FOR THE EARLY DETECTION OF COLORECTAL CANCER

- A simple blood test for patients
- Developed and validated clinically in Switzerland⁵
- A molecular test that measures immune system response
- The Colox test also detects adenomatous polyps, precursor lesions of cancer

HOW CAN I BE TESTED WITH **COLOX**?

Ask your physician for a **Colox** test prescription during your next periodic check-up







Your physician will inform you of the results received

A blood sample can be taken by your physician or directly by the diagnostic laboratory

INTERPRETATION OF COLOX RESULTS

IF YOUR **COLOX** IS NEGATIVE

- No cancer has been detected with a probability of 99.9%
- Follow the indications of your physician for periodic screening of colorectal cancer

IF YOUR **COLOX** IS POSITIVE

- The test detected an anomaly of the measured markers which could indicate the presence of adenomatous polyps (in 52% of cases) or of colorectal cancer (in only 2% of cases)
- In certain cases, the test could be positive without any presence of a colorectal lesion (false positive)
- Your physician will recommend additional analysis (colonoscopy)

References:

- ¹ Le cancer en Suisse, rapport 2015- Etat des lieux et évolutions. *Office fédéral de la statistique 2016*
- ² www.liguecancer.ch
- 3 Estimation
- ⁴ American Cancer Society
- ⁵ Ciarloni L et al. Development and clinical validation of a blood test based on 29-gene expression for early detection of colorectal cancer. *Clin Cancer Res. 2016 Apr 28*

novigenix

Novigenix SA

Biopôle IV - Route de la Corniche 3B CH-1066 Epalinges - SWITZERLAND T: +41 (0)21 552 07 30 - F: +41 (0)21 552 07 31

Email: colox@novigenix.com

